Is Obinituzumab the most Cost-Effective Biological Therapy for Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia in Colombia?

May 1, 2016, 00:00
10.1016/j.jval.2016.03.1602
https://www.valueinhealthjournal.com/article/S1098-3015(16)01670-3/fulltext
Title : Is Obinituzumab the most Cost-Effective Biological Therapy for Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia in Colombia?
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01670-3&doi=10.1016/j.jval.2016.03.1602
First page : A152
Section Title : Cancer - Cost Studies
Open access? : No
Section Order : 325
Categories :
Tags :
Regions :
ViH Article Tags :